Elan Alzheimer's Peptide Vaccine To Enter Phase II/III By End Of 2001

Elan's AN-1792 beta-amyloid peptide for immunization of Alzheimer's patients is expected to reach pivotal Phase II/III trials by the end of 2001, Elan Exec VP and Chief Scientific & Medical Officer Ivan Lieberburg, MD/PhD, told a press conference during the World Alzheimer's Conference in Washington, D.C.